University of Miami

Other

Ventrex Laboratories, Inc.

Alfred Chung

James W Ryan

Haralambos P Gavras

Novel inhibitors of angiotensin coverting enzyme having the general formula R - A - S - Z are disclosed as potent inhibitors of angiotensin converting enzyme and are useful anti-hypertensive agents.

Anti-hypertensive agents

Methods for the alkylation of substituted amines with trifluorate esters is disclosed.

Stereospecific synthesis of carboxyalkyl peptides

Novel inhibitors of angiotensin converting enzyme are disclosed which have the general formula ##STR1## wherein R.sub.1 and/or R.sub.3 form complex amides and imides thereof, R.sub.4 and R.sub.5 form with --N--C-- a 4-6 membered ring structure as described and the other R substituents are selected from a variety of disclosed groups.

Novel complex amido and imido derivatives of carboxyalkyl peptides

Novel thiolester compounds are disclosed which are orally effective angiotensin converting enzyme inhibitors useful in the treatment of mammalian hypertension. They have the formula,

Orally effective anti-hypertensive agents

Novel inhibitors of angiotensin converting enzyme having the general formula R - A - S - Z are disclosed as potent inhibitors of angiotensin converting enzyme and are useful anti-hypertensive agents.

ACE inhibitors containing amino acid esters of thiopropanoyl-L-3,4-dehydroproline are disclosed.

Novel compounds are disclosed as potent inhibitors of angiotensin converting enzyme and as orally effective antihypertensive agents. The compounds have the general formula: ##STR1##

The compounds, N-[3-(benzoylphenylalanylthio)-2-D-methylpropanoyl]-L-proline (I), N-(2-benzoylphenylalanylthiopropanoyl)-L-proline (II) and N-(3-benzoylphenylalanylthiopropanoyl)-L-proline (III) are disclosed. These compounds are potent inhibitors of serum angiotensin converting enzyme.

Inhibitors of angiotensin converting enzyme

Inhibitors of angiotensin converting enzyme which have the formula: ##STR1## wherein R is hydrogen, formyl, acetyl propanoyl, butanoyl, phenylacetyl, phenylpropanoyl, benzoyl, cyclopentanecarbonyl, tert-butyloxycarbonyl, cyclopentanecarbonyl-L-lysyl, pyro-L-glutamyl-L-lysyl, L-lysyl, L-arginyl or pyro-L-glutamyl;

Inhibitors of angiotensin converting enzyme which are physiologically acceptable salts of compounds which have the formula: ##STR1## wherein R is hydrogen, formyl, acetyl, propanoyl, butanoyl, phenylacetyl, phenylpropanoyl, benzoyl, cyclopentanecarbonyl, tert-butyloxycarbonyl, cyclopentanecarbonyl-L-lysyl, pyro-L-glutamyl-L-lysyl, L-lysyl, L-arginyl or pyro-L-glutamyl;

Novel inhibitors of angiotensin converting enzyme having the general formula R--A--S--Z are disclosed as potent inhibitors of angiotensin converting enzyme and are useful anti-hypertensive agents.

Novel inhibitors of ACE are disclosed as potent inhibitors of angiotensin converting enzyme and as orally effective anti-hypertensive agents. The compounds have the general formula: ##STR1##

Growing community of inventors

Miami, FL, United States of America

Alfred Chung